TY - JOUR
T1 - Bortezomib-induced acute interstitial nephritis
AU - Cheungpasitporn, Wisit
AU - Leung, Nelson
AU - Rajkumar, S. Vincent
AU - Cornell, Lynn D.
AU - Sethi, Sanjeev
AU - Angioi, Andrea
AU - Fervenza, Fernando C.
N1 - Publisher Copyright:
© 2015 The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Acute interstitial nephritis (AIN) is one of the important causes of acute kidney injury (AKI) resulting from inflammatory tubulointerstitial injury induced by medications, infections and systemic diseases. Bortezomib has been increasingly used especially in renal related indications such as multiple myeloma and monoclonal gammopathy of renal significance. Severe allergic reactions from bortezomib treatment including AIN have not been described in the literature. We report a 47-year-old white man who developed biopsy-proven allergic AIN after treatment with bortezomib for his C3 glomerulonephritis. The patient's kidney function improved after treatment with glucocorticoid therapy and discontinuation of bortezomib, but worsened with recurrent AKI episode after re-initiation of bortezomib. His renal function improved after glucocorticoid therapy and discontinuation of bortezomib. To our knowledge, this is the first report of a biopsy-proven AIN from bortezomib.
AB - Acute interstitial nephritis (AIN) is one of the important causes of acute kidney injury (AKI) resulting from inflammatory tubulointerstitial injury induced by medications, infections and systemic diseases. Bortezomib has been increasingly used especially in renal related indications such as multiple myeloma and monoclonal gammopathy of renal significance. Severe allergic reactions from bortezomib treatment including AIN have not been described in the literature. We report a 47-year-old white man who developed biopsy-proven allergic AIN after treatment with bortezomib for his C3 glomerulonephritis. The patient's kidney function improved after treatment with glucocorticoid therapy and discontinuation of bortezomib, but worsened with recurrent AKI episode after re-initiation of bortezomib. His renal function improved after glucocorticoid therapy and discontinuation of bortezomib. To our knowledge, this is the first report of a biopsy-proven AIN from bortezomib.
KW - C3 glomerulonephritis
KW - acute interstitial nephritis
KW - bortezomib
KW - monoclonal gammopathy
KW - nephrotoxicity
UR - http://www.scopus.com/inward/record.url?scp=84936772291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936772291&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfv222
DO - 10.1093/ndt/gfv222
M3 - Article
C2 - 26109684
AN - SCOPUS:84936772291
VL - 30
SP - 1225
EP - 1229
JO - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress
JF - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress
SN - 0931-0509
IS - 7
ER -